Chem. J. Chinese Universities ›› 2017, Vol. 38 ›› Issue (4): 591.doi: 10.7503/cjcu20160798

• Organic Chemistry • Previous Articles     Next Articles

Design, Synthesis and Biological Evaluation of Novel O2-(2,4-Dinitrophenyl)diazeniumdiolates as Anti-tumor Agents

YAN Chang1, ZOU Yu1, FU Junjie2, HUANG Zhangjian1, ZHANG Dayong1,*(), ZHANG Yihua1,*()   

  1. 1. Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery,China Pharmaceutical University, Nanjing 210009, China
    2. School of Pharmacy, Nanjing Medical University, Nanjing 211166, China
  • Received:2016-11-16 Online:2017-04-10 Published:2017-03-13
  • Contact: ZHANG Dayong,ZHANG Yihua E-mail:cpuzdy@163.com;zyhtgd@163.com
  • Supported by:
    † Supported by the National Natural Science Foundation of China(Nos;81273378, 21372261, 81673305)

Abstract:

O2-(2,4-Dinitrophenyl)diazeniumdiolate(PABA/NO) possesses significant anticancer activity but poor stability. To search for new agents with stronger activity and better stability, PABA/NO was employed as a lead compound. A series of PABA/NO analogues was designed and synthesized with an appropriate secondary amine as the amine moiety in the diazeniumdiolate structure, and replacing the ester bond of the benzene ring with a carbon-nitrogen bond. The structures of the synthesized compounds were characterized by means of 1H NMR, 13C NMR and HRMS. All the target compounds showed strong inhibitory effects against colon cancer HCT-116 cells to a varying extent. Compound 4h(IC50=7.945±0.421 μmol/L) was the most potent against HCT-116 cells, superior to PABA/NO (IC50=12.134±0.675 μmol/L). There was observed that a positive correlation existed between activity and NO release levels. The most active compound 4h released higher levels of NO in colon cancer cells than that in the normal ones. In addition, compound 4h showed better stability in plasma than PABA/NO. These results suggested compound 4h might be a promising anticancer agent, and worthy of further study.

Key words: O2-(2, 4-Dinitrophenyl)diazeniumdiolate, HCT-116 cell, Anti-tumor activity, Stability

CLC Number: 

TrendMD: